Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies

Cancer Immunol Immunother. 2022 Jul;71(7):1771-1775. doi: 10.1007/s00262-021-03101-4. Epub 2021 Nov 8.

Abstract

Here, we report a novel experimental setup to perform adoptive transfer of gene-edited B cells using humanized immune system mice by infusing autologous HIS mouse-derived human B cells "educated" in a murine context and thus rendered tolerant to the host. The present approach presents two advantages over the conventional humanized PBMC mouse models: (i) it circumvents the risk of xenogeneic graft-versus-host reaction and (ii) it mimics more closely human immune responses, thus favoring clinical translation. We show that the frequencies and numbers of transduced B cells in recipient's spleens one week post-transfer are within the range of the size of the pre-immune B cell population specific for a given protein antigen in the mouse. They are also compatible with the B cell numbers required to elicit a sizeable immune response upon immunization. Altogether, our findings pave the way for future studies aiming at assessing therapeutic interventions involving B cell reprogramming for instance by an antibody transgene in a "humanized" hematopoietic setting.

Keywords: B cell adoptive transfer; Cell therapy; Gene therapy; Humanized immune system.

MeSH terms

  • Adoptive Transfer
  • Animals
  • Disease Models, Animal
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukocytes, Mononuclear*
  • Mice
  • Mice, SCID